Skip to main content

Nonprofit · EIN 04-3460220

THE PROGERIA RESEARCH FOUNDATION INC

Also known as PREMATURE AGING IN CHILD-PROG RES F

Tax-exempt · PEABODY, MA 01961

Financials

$2.2M$3.9M2023$3.7M$5.9M2024$4.5M$4.2M2025
Revenue Expenses · by fiscal year end
Financials of THE PROGERIA RESEARCH FOUNDATION INC by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2025990$4,458,016$4,163,643$294,373$49,979,002$526,805$49,452,197
December 31, 2024990$3,650,308$5,902,368-$2,252,060$48,028,500$627,829$47,400,671
December 31, 2023990$2,231,500$3,929,965-$1,698,465$48,844,685$593,519$48,251,166
Financial details: 990 for the year ended December 31, 2025

Revenue

Contributions, gifts and grants
$2,020,617
of which government grants
$98,625
Program service revenue
$0
Investment income
$2,433,984
Net gain from sales of assets
$559,351
Net income from fundraising events
$3,415
Other revenue
$3,415

Expenses

Grants and similar amounts paid
$0
Compensation of officers, directors and key employees
$608,187
Other salaries and wages
$556,167
Salaries, compensation and benefits (total)
$1,300,190
Professional fundraising fees
$0
Legal fees
$280,397
Accounting fees
$64,008
Occupancy
$55,180
Travel
$9,240
Depreciation
$19,319
Program services (functional)
$3,024,716
Management and general (functional)
$930,856
Fundraising (functional)
$208,071

Balance sheet and other

Total assets, start of year
$48,028,500
Total assets, end of year
$49,979,002
Total liabilities, end of year
$526,805
Net assets, end of year
$49,452,197
Land, buildings and equipment
$20,447
Publicly traded securities
$41,294,699
Net assets without donor restrictions
$49,332,586
Net assets with donor restrictions
$119,611
Gross receipts
$7,933,487
Employees
15
Volunteers
60
Year formed
1999
State of legal domicile
MA

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

NameTitleHours / weekCompensationOther / benefits
BARBARA NATKECHIEF BUSINESS OFFICER
Key employee
40$319,523$0
AUDREY GORDONPRESIDENT & EXECUTIVE DIRECTOR
Officer
40$256,385$32,279
MICHELLE FINODIRECTOR OF DEVELOPMENT
Highest-paid employee
40$114,478$6,031
GINA INCROVATODIRECTOR OF OPERATIONS
Highest-paid employee
40$113,512$0
SCOTT BERNSDIRECTOR
Trustee or director
1$0$0
PAULA KELLYTREASURER/DIRECTOR
Trustee or director, Officer
1$0$0
KAREN BALLACKDIRECTOR
Trustee or director
1$0$0
SANDRA BRESNICKDIRECTOR
Trustee or director
1$0$0
KIM PARATORECLERK/DIRECTOR
Trustee or director, Officer
1$0$0
JOHN MAROZZIDIRECTOR
Trustee or director
1$0$0
LARRY MILLSDIRECTOR
Trustee or director
1$0$0
LIZA MORRISDIRECTOR
Trustee or director
1$0$0
MATTHEW WINTERSDIRECTOR
Trustee or director
1$0$0
MARK KIERANDIRECTOR
Trustee or director
1$0$0
ALAN BROGDONDIRECTOR
Trustee or director
1$0$0
990 for the year ended December 31, 2024: 15 people
NameTitleHours / weekCompensationOther / benefits
BARBARA NATKECHIEF BUSINESS OFFICER
Key employee
40$307,689$755
AUDREY GORDONPRESIDENT
Officer
40$230,000$20,427
JASON CHRISTIANSENGENERAL COUNSEL
Highest-paid employee
40$173,656$0
MICHELLE FINODIRECTOR OF DEVELOPMENT
Highest-paid employee
40$100,253$0
SCOTT BERNSDIRECTOR
Trustee or director
1$0$0
PAULA KELLYTREASURER/DIRECTOR
Trustee or director, Officer
1$0$0
KAREN BALLACKDIRECTOR
Trustee or director
1$0$0
SANDRA BRESNICKDIRECTOR
Trustee or director
1$0$0
KIM PARATORECLERK/DIRECTOR
Trustee or director, Officer
1$0$0
JOHN MAROZZIDIRECTOR
Trustee or director
1$0$0
LARRY MILLSDIRECTOR
Trustee or director
1$0$0
LIZA MORRISDIRECTOR
Trustee or director
1$0$0
MATTHEW WINTERSDIRECTOR
Trustee or director
1$0$0
MARK KIERANDIRECTOR
Trustee or director
1$0$0
ALAN BROGDONDIRECTOR
Trustee or director
1$0$0
990 for the year ended December 31, 2023: 12 people
NameTitleHours / weekCompensationOther / benefits
AUDREY GORDONPRESIDENT
Officer
40$235,000$20,427
BARBARA NATKECHIEF BUSINESS OFFICER
Highest-paid employee
40$143,475$755
SCOTT BERNSDIRECTOR
Trustee or director
1$0$0
PAULA KELLYTREASURER/DIRECTOR
Trustee or director, Officer
1$0$0
KAREN BALLACKDIRECTOR
Trustee or director
1$0$0
SANDRA BRESNICKDIRECTOR
Trustee or director
1$0$0
KIM PARATORECLERK/DIRECTOR
Trustee or director, Officer
1$0$0
JOHN MAROZZIDIRECTOR
Trustee or director
1$0$0
LARRY MILLSDIRECTOR
Trustee or director
1$0$0
LIZA MORRISDIRECTOR
Trustee or director
1$0$0
MATTHEW WINTERSDIRECTOR
Trustee or director
1$0$0
MARK KIERANDIRECTOR
Trustee or director
1$0$0

Address and contacts

Address (IRS master file)
PO BOX 3453, PEABODY, MA 01961-3453
In care of
% AUDREY S GORDON
Principal officer (990 for 2025)
AUDREY GORDON ESQ, 200 LAKE STREET, PEABODY, MA 01960
Signed the 990
AUDREY GORDON ESQ, PRESIDENT, EXECUTIVE DIRECTOR
Phone
(978) 535-2594
Return prepared by
CITRIN COOPERMAN ADVISORS LLC

Mission

DISCOVER TREATMENTS & CURE FOR PROGERIA & ITS AGING RELATED DISORDERS, INCLUDING HEART DISEASE.

990 for the year ended December 31, 2025

Program accomplishments

  • PROGERIA DRUG TRIAL: THE PROGERIA RESEARCH FOUNDATION AND BOSTON CHILDREN'S HOSPITAL CONTINUE THEIR PARTNERSHIP FOR CONDUCTING CLINICAL DRUG TRIALS FOR CHILDREN WITH PROGERIA. THE CLINICAL TRIAL TEAM: A TEAM OF PROFESSIONALS AT BOSTON CHILDREN'S HOSPITAL AND BRIGHAM & WOMEN'S HOSPITAL WORKING WITH CHILDREN WITH PROGERIA FROM AROUND THE GLOBE.
    Expenses $927,130
  • FUTURE TRIAL EFFORTS: PRF ENGAGES MEMBERS IN THE SCIENTIFIC COMMUNITY WITH EXPERTISE IN VARIOUS DRUGS AND/OR GENETIC THERAPIES FOR THE TREATMENT AND POTENTIAL CURE FOR PROGERIA. THE INVESTIGATION AND COLLABORATIVE EVALUATION OF DRUG THERAPIES IS PURSUED TO IDENTIFY DRUG CANDIDATES/GENETIC THERAPIES THAT CAN LEAD TO FUTURE CLINICAL TRIALS.
    Expenses $574,601
  • DIAGNOSTIC TESTING: PRF DEVELOPED A DIAGNOSTIC TEST FOR PROGERIA IN THE WAKE OF THE 2003 GENE DISCOVERY SO THOSE WITH PROGERIA, THEIR FAMILIES AND MEDICAL CARETAKERS CAN FOR THE FIRST TIME BE GIVEN A DEFINITIVE SCIENTIFIC DIAGNOSIS. THIS CAN TRANSLATE INTO EARLIER DIAGNOSIS, FEWER MISDIAGNOSES AND EARLY MEDICAL INTERVENTION TO ENSURE A BETTER QUALITY OF LIFE FOR THOSE WITH PROGERIA.(SEE SCHEDULE O FOR CONTINUATION)MEDICAL & RESEARCH DATABASE: THE DATABASE IS A COLLECTION OF MEDICAL RECORDS OF PROGERIA PATIENTS FROM ALL OVER THE WORLD. THE DATA IS RIGOROUSLY ANALYZED TO DETERMINE THE BEST COURSE OF TREATMENTS TO IMPROVE THE PATIENTS' QUALITY OF LIFE. THIS INFORMATION IS INVALUABLE FOR THE ATTENDING PHYSICIAN TO GUIDE THE FAMILY THROUGH THE BEST COURSE OF ACTION. DATABASE MATERIAL WAS USED TO CREATE PRF'S COMPREHENSIVE HEALTHCARE RECOMMENDATIONS HANDBOOK ON PROGERIA AIMED AT OPTIMIZING QUALITY OF LIFE. THE DATABASE WAS ALSO CRITICAL IN DETERMINING THE PRIMARY CLINICAL OUTCOME PARAMETER FOR PAST PROGERIA CLINICAL DRUG TRIALS.PRF TRANSLATION PROGRAM: IN TOUCH WITH THE WORLD. WITH A PROMINENT GLOBAL OUTREACH, PRF ELIMINATES BARRIERS OF COMMUNICATION FOR PATIENTS AND THEIR FAMILIES AROUND THE WORLD. THIS INITIATIVE HAS SUCCEEDED IN TRANSLATING PRF PROGRAM AND MEDICAL CARE MATERIALS INTO OVER 3 DOZEN DIFFERENT LANGUAGES.THE PROGERIA HANDBOOK: A GUIDE FOR FAMILIES AND HEALTH CARE PROVIDERS OF CHILDREN AND YOUNG ADULTS WITH PROGERIA THAT INCLUDES DAILY CARE RECOMMENDATIONS AND EXTENSIVE TREATMENT GUIDELINES. IT IS PUBLISHED IN ENGLISH AND SEVERAL OTHER LANGUAGES TO ALLOW ITS USE THROUGHOUT THE WORLD.INTERNATIONAL PROGERIA REGISTRY: CONSISTS OF CENTRALIZED CONTACT AND OTHER INFORMATION ON CHILDREN AND FAMILIES LIVING WITH PROGERIA. THE REGISTRY PROVIDES DATA ON PATIENT DEMOGRAPHICS AND ASSURES RAPID DISTRIBUTION OF ANY NEW INFORMATION THAT MAY BENEFIT THOSE WITH PROGERIA.SCIENTIFIC CONFERENCES; PRF ORGANIZES MEETINGS THAT BRING TOGETHER SCIENTISTS AND CLINICIANS FROM ALL OVER THE WORLD TO SHARE THEIR EXPERTISE AND CUTTING EDGE SCIENTIFIC DATA, AND FOSTER COLLABORATION IN THE FIGHT AGAINST PROGERIA AND OTHER AGING RELATED CONDITIONS.CLINICAL TRIALS: IN 2025, 7 CHILDREN AND YOUNG ADULTS CAME TO BOSTON TO UNDERGO TESTING AND OBTAIN LONAFARNIB FOR THE PROLON 3 (LONAFARNIB EXTENSION) TRIAL, WHICH ALLOWS CHILDREN AND YOUNG ADULTS WHO ARE UNABLE TO OBTAIN LONAFARNIB IN THEIR HOME COUNTRY TO RECEIVE THIS LIFE EXTENDING TREATMENT THROUGH THIS TRIAL, WHILE ALSO GATHERING IMPORTANT DISEASE-RELATED DATA. IN 2025, THE TEAM CONTINUES TO GATHER DATA FROM THE ONGOING CLINICAL DRUG TRIAL. IN ADDITION, PRF COLLABORATED WITH PRG SCIENCE & TECHNOLOGY IN A TRIAL INVOLVING THE DRUG PROGERININ. TEN CHILDREN AND YOUNG ADULTS CAME TO BOSTON THREE TIMES IN 2025 TO PARTICIPATE IN THE TRIAL. ONE OF THE 10 PARTICIPANTS ONE ALSO PARTICIPATED IN THE PROLON 3 TRIAL SIMULTANEOUSLY DURING ONE OF THE VISITS.
    Expenses $1,522,985

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026990 on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990 on file

IRS record

EIN
04-3460220
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
1999
Accounting year ends
December
Files
Form 990 or 990-EZ
Assets (IRS master file)
$49,979,002
Income (IRS master file)
$7,933,487

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2025$4,458,016$4,163,643$49,979,002XML
990December 2024$3,650,308$5,902,368$48,028,500XML
990December 2023$2,231,500$3,929,965$48,844,685XML
990December 2022$1,793,850$3,126,766$47,596,733IRS
990December 2021–––IRS
990December 2020–––IRS
990December 2018–––IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 04-3460220).

Questions about THE PROGERIA RESEARCH FOUNDATION INC

What is the EIN of THE PROGERIA RESEARCH FOUNDATION INC?
The employer identification number (EIN) of THE PROGERIA RESEARCH FOUNDATION INC is 04-3460220.
Is THE PROGERIA RESEARCH FOUNDATION INC tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1999.
Are donations to THE PROGERIA RESEARCH FOUNDATION INC tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does THE PROGERIA RESEARCH FOUNDATION INC file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of THE PROGERIA RESEARCH FOUNDATION INC due?
The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
When did THE PROGERIA RESEARCH FOUNDATION INC last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2025.
Who is the principal officer of THE PROGERIA RESEARCH FOUNDATION INC?
The 990 for the year ended December 31, 2025 names AUDREY GORDON ESQ.
Who are the officers and directors of THE PROGERIA RESEARCH FOUNDATION INC?
The 990 for the year ended December 31, 2025 lists 15 people; 4 received compensation from the organization, the highest $319,523 (BARBARA NATKE, CHIEF BUSINESS OFFICER).
How much revenue does THE PROGERIA RESEARCH FOUNDATION INC have?
On its 990 for the year ended December 31, 2025 it reported revenue of $4,458,016, expenses of $4,163,643 and total assets of $49,979,002 at year end.

Other nonprofits in PEABODY

All nonprofits in PEABODY · Massachusetts · Medical research